Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
4000 participants
OBSERVATIONAL
2024-07-25
2028-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Biomarkers in Patients of Sepsis Complicated With Acute Respiratory Distress Syndrome (ARDS)
NCT04552821
Explore Potential Plasma and BALF Immunometabolic and Lipidomic Biomarkers for Identifying ARDS Endotypes
NCT05451342
Validation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter Cohort Study
NCT07289711
An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States
NCT06272942
Lung Injury Prediction Study
NCT00889772
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A (full study protocol - written informed consent)
Cohort A is the cohort of APS study participants who have provided written informed consent for participation in the APS phenotyping study. Cohort A may participate in all study procedures in the APS phenotyping study.
Blood collection
Blood will be collected from a catheter ("IV") that is already in place or using a needle stick into a vein.
Blood will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort).
Urine Collection
Urine will be collected through a urinary catheter that is already in place or by urinating into a cup.
Urine will be collected in hospital only (Cohorts A, B)
Nasal, oral, and rectal swabs
Nasal, oral, and rectal swabs inserted into the nose, mouth, and rectum, respectively. The swabs will be rubbed inside the cavity and then removed the swab.
Oral and nasal swabs will also be collected in hospital (Cohort A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort). Rectal swabs will be collected in hospital only (Cohorts A, B).
Stool collection
Stool will be collected either in a cup after defecation or by collecting it from a tube or bag that may already be in place that is catching stool.
Stool will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization (Long Term Outcomes Cohort).
Heat Moisture Exchange Filter collection
An HME filter is a sponge that is placed in the tubing between a patient and breathing machine. It reduces the amount of heat and moisture a patient loses when on a breathing machine. Moisture from breath is collected in this filter. The filter is changed every few hours. When the filter is changed, it will be saved to collect the moisture that it contains and run tests on it.
HME filters will be collected in hospital on intubated patients only (Cohorts A, B).
Tracheal Aspirate sample collection
Patients on a breathing machine have a breathing tube in their trachea that connects their lungs to the breathing machine. A smaller tube, called a suction catheter, will be placed through the larger tube and fluid will be gently sucked out.
Tracheal aspirate will be collected in hospital on intubated patients only (Cohorts A, B)
Non-bronchoscopic bronchoalveolar lavage (NBBAL)
The NBBAL procedure involves putting a flexible rubber tube through the breathing tube into the airway of one of the lungs. A small amount of fluid is injected into the lung and then a gentle suction is used to collect fluid. Only patients who pass a safety screen showing that they are not at high risk for complications will have the NBBAL procedure performed.
NBBAL will be performed in hospital on intubated patients only (Cohort A)
Surveys
Participants will be contacted by email, text, and /or phone to give updates about their health. These surveys will ask questions about quality of life, mental health, return to work, and re-admission to the hospital. (Cohort A)
Cohort B (alteration study protocol - alteration of informed consent)
Cohort B is the cohort of APS study participants who are enrolled in the study under alteration of informed consent. Cohort B will participate in a modified set of procedures which omits procedures considered greater than minimal risk.
Blood collection
Blood will be collected from a catheter ("IV") that is already in place or using a needle stick into a vein.
Blood will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort).
Urine Collection
Urine will be collected through a urinary catheter that is already in place or by urinating into a cup.
Urine will be collected in hospital only (Cohorts A, B)
Nasal, oral, and rectal swabs
Nasal, oral, and rectal swabs inserted into the nose, mouth, and rectum, respectively. The swabs will be rubbed inside the cavity and then removed the swab.
Oral and nasal swabs will also be collected in hospital (Cohort A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort). Rectal swabs will be collected in hospital only (Cohorts A, B).
Stool collection
Stool will be collected either in a cup after defecation or by collecting it from a tube or bag that may already be in place that is catching stool.
Stool will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization (Long Term Outcomes Cohort).
Heat Moisture Exchange Filter collection
An HME filter is a sponge that is placed in the tubing between a patient and breathing machine. It reduces the amount of heat and moisture a patient loses when on a breathing machine. Moisture from breath is collected in this filter. The filter is changed every few hours. When the filter is changed, it will be saved to collect the moisture that it contains and run tests on it.
HME filters will be collected in hospital on intubated patients only (Cohorts A, B).
Tracheal Aspirate sample collection
Patients on a breathing machine have a breathing tube in their trachea that connects their lungs to the breathing machine. A smaller tube, called a suction catheter, will be placed through the larger tube and fluid will be gently sucked out.
Tracheal aspirate will be collected in hospital on intubated patients only (Cohorts A, B)
Long-term Outcomes Cohort
The Long-term Outcomes Cohort consists of a subset of participants with written informed consent for study participation (Cohort A) who complete in-person post-hospital study assessments. These in-person study visits are scheduled at 3-, 6-, and 12-months after initial enrollment in the hospital. Interventions/exposures are denoted for this group for study procedures that are completed during an in-person post-hospital visit.
Blood collection
Blood will be collected from a catheter ("IV") that is already in place or using a needle stick into a vein.
Blood will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort).
Nasal, oral, and rectal swabs
Nasal, oral, and rectal swabs inserted into the nose, mouth, and rectum, respectively. The swabs will be rubbed inside the cavity and then removed the swab.
Oral and nasal swabs will also be collected in hospital (Cohort A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort). Rectal swabs will be collected in hospital only (Cohorts A, B).
Stool collection
Stool will be collected either in a cup after defecation or by collecting it from a tube or bag that may already be in place that is catching stool.
Stool will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization (Long Term Outcomes Cohort).
Short physical performance battery
At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort)
Chair Stand Test: For this test the participant will sit in a chair. They will then stand as quickly as possible without using their upper body to assist them.
Balance Test: For this test the participant will stand unsupported for 10 seconds with their feet in 3 different positions.
4-meter walk: For this test the participant will walk 4 meters as quickly as possible.
Hand grip strength
At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):
The participant will squeeze a machine called a hand-held dynamometer 3 times with all their strength.
CNS Vital Signs
At visits 3, 6, and 12 months following hospitalization (Cohort A - Long-term Outcomes Cohort):
The participant will sit at a computer and follow the prompts on the screen. This test takes about 45 minutes.
Muscle Ultrasound
At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):
The participant will undergo ultrasound on the quadriceps muscle on the dominant side of their body.
Muscle Strength
At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):
A dynamometer will be used to measure muscle strength in the dominant leg.
Spirometry
At a visit 12 months following hospitalization (Long-term Outcomes Cohort):
The participant will have a clip placed on their nose and will be given a plastic mouthpiece that is connected to a machine called a spirometer. They will place their lips tightly around the mouthpiece and take in as big and deep of a breath as possible and then blow out as hard and fast as they can.
Lung Diffusion Testing (DLCO)
At a visit 12 months following hospitalization (Long-term Outcomes Cohort):
The participant will have a clip on their nose. They will put their mouth over a mouthpiece that is attached to a machine. This machine will deliver a small amount of carbon dioxide when they breathe in and will also record the results of the test. They will then take a few normal breaths. Next they will inhale deeply and exhale completely. They will breathe in quickly through their mouth and hold their breath for 10 seconds or as long as they can. Then they will breathe out.
Chest CT Scan
At a visit 12 months following hospitalization (Long-term Outcomes Cohort):
The participant will undergo a Chest Computed Tomography (CT) scan which uses special X-ray equipment to take detailed pictures of the lungs.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood collection
Blood will be collected from a catheter ("IV") that is already in place or using a needle stick into a vein.
Blood will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort).
Urine Collection
Urine will be collected through a urinary catheter that is already in place or by urinating into a cup.
Urine will be collected in hospital only (Cohorts A, B)
Nasal, oral, and rectal swabs
Nasal, oral, and rectal swabs inserted into the nose, mouth, and rectum, respectively. The swabs will be rubbed inside the cavity and then removed the swab.
Oral and nasal swabs will also be collected in hospital (Cohort A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort). Rectal swabs will be collected in hospital only (Cohorts A, B).
Stool collection
Stool will be collected either in a cup after defecation or by collecting it from a tube or bag that may already be in place that is catching stool.
Stool will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization (Long Term Outcomes Cohort).
Heat Moisture Exchange Filter collection
An HME filter is a sponge that is placed in the tubing between a patient and breathing machine. It reduces the amount of heat and moisture a patient loses when on a breathing machine. Moisture from breath is collected in this filter. The filter is changed every few hours. When the filter is changed, it will be saved to collect the moisture that it contains and run tests on it.
HME filters will be collected in hospital on intubated patients only (Cohorts A, B).
Tracheal Aspirate sample collection
Patients on a breathing machine have a breathing tube in their trachea that connects their lungs to the breathing machine. A smaller tube, called a suction catheter, will be placed through the larger tube and fluid will be gently sucked out.
Tracheal aspirate will be collected in hospital on intubated patients only (Cohorts A, B)
Non-bronchoscopic bronchoalveolar lavage (NBBAL)
The NBBAL procedure involves putting a flexible rubber tube through the breathing tube into the airway of one of the lungs. A small amount of fluid is injected into the lung and then a gentle suction is used to collect fluid. Only patients who pass a safety screen showing that they are not at high risk for complications will have the NBBAL procedure performed.
NBBAL will be performed in hospital on intubated patients only (Cohort A)
Surveys
Participants will be contacted by email, text, and /or phone to give updates about their health. These surveys will ask questions about quality of life, mental health, return to work, and re-admission to the hospital. (Cohort A)
Short physical performance battery
At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort)
Chair Stand Test: For this test the participant will sit in a chair. They will then stand as quickly as possible without using their upper body to assist them.
Balance Test: For this test the participant will stand unsupported for 10 seconds with their feet in 3 different positions.
4-meter walk: For this test the participant will walk 4 meters as quickly as possible.
Hand grip strength
At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):
The participant will squeeze a machine called a hand-held dynamometer 3 times with all their strength.
CNS Vital Signs
At visits 3, 6, and 12 months following hospitalization (Cohort A - Long-term Outcomes Cohort):
The participant will sit at a computer and follow the prompts on the screen. This test takes about 45 minutes.
Muscle Ultrasound
At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):
The participant will undergo ultrasound on the quadriceps muscle on the dominant side of their body.
Muscle Strength
At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):
A dynamometer will be used to measure muscle strength in the dominant leg.
Spirometry
At a visit 12 months following hospitalization (Long-term Outcomes Cohort):
The participant will have a clip placed on their nose and will be given a plastic mouthpiece that is connected to a machine called a spirometer. They will place their lips tightly around the mouthpiece and take in as big and deep of a breath as possible and then blow out as hard and fast as they can.
Lung Diffusion Testing (DLCO)
At a visit 12 months following hospitalization (Long-term Outcomes Cohort):
The participant will have a clip on their nose. They will put their mouth over a mouthpiece that is attached to a machine. This machine will deliver a small amount of carbon dioxide when they breathe in and will also record the results of the test. They will then take a few normal breaths. Next they will inhale deeply and exhale completely. They will breathe in quickly through their mouth and hold their breath for 10 seconds or as long as they can. Then they will breathe out.
Chest CT Scan
At a visit 12 months following hospitalization (Long-term Outcomes Cohort):
The participant will undergo a Chest Computed Tomography (CT) scan which uses special X-ray equipment to take detailed pictures of the lungs.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Admitted (or planned to be admitted) to an intensive care unit (ICU) or other in-patient hospital location where IV vasopressors or advanced respiratory support (invasive mechanical ventilation, non-invasive ventilation, or high flow nasal cannula) are routinely provided (referred to as an "eligible unit.")
3. Acute cardiovascular or pulmonary organ dysfunction defined by meeting at least one of the two criteria below:
* New receipt of invasive mechanical ventilation, non-invasive ventilation, high flow nasal cannula, or supplemental oxygen at a flow rate of ≥ 6 lpm for acute hypoxemia.
a. Patients who use chronic oxygen therapy are eligible to participate if they are receiving at least 6 lpm higher than their baseline oxygen requirement (e.g., a patient on 3 lpm O2 at baseline is eligible if they require ≥9 lpm for hypoxemia) or are started on advanced respiratory support (invasive mechanical ventilation, non- invasive ventilation, or high flow nasal cannula).
* Receipt of intravenous infusion of a vasopressor medication for at least one hour.
4. Acute cardiovascular or pulmonary organ dysfunction (inclusion criterion #3) is attributed to an acute inflammatory condition, including but not limited to any of the following:
* Any infection including pneumonia.
* Aspiration pneumonitis.
* Pancreatitis.
* Auto-inflammatory condition such as:
1. Hemophagocytic lymphohistiocytosis.
2. Suspected acute rheumatologic or auto-immune disease with pulmonary or cardiovascular manifestations.
3. Suspected cryptogenic organizing pneumonia presenting acutely.
4. Suspected diffuse alveolar hemorrhage.
5. Suspected acute anaphylaxis.
6. Suspected acute pulmonary drug toxicity.
Exclusion Criteria
2. Acute cardiovascular or pulmonary organ dysfunction (inclusion criterion #3) has been present for \> 48 hours.
3. Patient has been in an eligible unit (inclusion criterion #2) for more than 120 hours (five days).
4. Patient is no longer expected to meet the acute cardiovascular or pulmonary organ dysfunction inclusion criterion (inclusion criterion #3) 24 hours after enrollment.
5. Patient desires comfort measures only.
6. Patient is a prisoner.
7. Patient had out-of-hospital cardiac arrest leading to this hospitalization.
8. Residence immediately before this hospitalization in a long-term acute care facility.
9. Presence of tracheostomy for respiratory failure.
10. Home invasive mechanical ventilation or non-invasive ventilation (except patients with non-invasive ventilation prescribed as a treatment for a sleep disorder may participate).
11. Suspected cause of the patient's acute cardiovascular and/or pulmonary dysfunction (inclusion criterion #3) is an alternative condition (not ARDS, pneumonia, or sepsis), including but not limited to the list below:
* Drug overdose (without aspiration, lung injury, pneumonia, or infection).
* Trauma (without aspiration, pneumonia, or infection).
* Chronic lung disease without suspected infection, aspiration, or inflammation.
* Asthma, chronic obstructive pulmonary disease (COPD), sarcoidosis, interstitial lung disease, neuromuscular respiratory failure.
* Status epilepticus.
* Acute pulmonary embolism.
* Acute decompensated heart failure.
* Diabetic ketoacidosis.
* Acute stroke or intracranial hemorrhage.
* Acute bleeding (GI bleeding, post-procedural bleeding, hemolysis).
* Cytokine release syndrome due to chemotherapy.
12. Inability or unwillingness to complete study-specified blood draws, for example, due to local policies about hemoglobin thresholds for research blood draws.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanderbilt University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wesley Self
APS Consortium Coordinating Center Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wesley H. Self, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fresno Community Hospital and Medical Center
Fresno, California, United States
Stanford University
Palo Alto, California, United States
San Francisco General Hospital
San Francisco, California, United States
University of California, San Francisco
San Francisco, California, United States
University of Colorado, Denver
Denver, Colorado, United States
Denver Health and Hospital Authority
Denver, Colorado, United States
National Jewish Health
Denver, Colorado, United States
University of Chicago
Chicago, Illinois, United States
Johns Hopkins Univeristy
Baltimore, Maryland, United States
University of Michigan
Ann Arbor, Michigan, United States
Washington University School of Medicine
St Louis, Missouri, United States
Duke University
Durham, North Carolina, United States
University of Cincinnati
Cincinnati, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Meharry Medical College
Nashville, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Intermountain Medical Center
Murray, Utah, United States
University of Utah
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Eyad Almasri, MD
Role: primary
Angela Rogers, MD
Role: primary
Carolyn Hendrickson, MD, MPH
Role: primary
Carolyn Calfee, MD
Role: primary
Marc Moss, MD
Role: primary
Ivor Douglas, MD, FRCP
Role: primary
William Janssen, MD
Role: primary
Krysta Wolfe, MD
Role: primary
Dale Needham, MD, PhD
Role: primary
Robert Hyzy, MD
Role: primary
Pratik Sinha, MBChB, PhD
Role: primary
Christina Barkauskas, MD
Role: primary
R. Duncan Hite, MD
Role: primary
Nuala Meyer, MD, MS
Role: primary
Richard Freemont, MD
Role: primary
Samuel Brown, MD, MS
Role: primary
Estelle Harris, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Semler MW, Bernard GR, Aaron SD, Angus DC, Biros MH, Brower RG, Calfee CS, Colantuoni EA, Ferguson ND, Gong MN, Hopkins RO, Hough CL, Iwashyna TJ, Levy BD, Martin TR, Matthay MA, Mizgerd JP, Moss M, Needham DM, Self WH, Seymour CW, Stapleton RD, Thompson BT, Wunderink RG, Aggarwal NR, Reineck LA. Identifying Clinical Research Priorities in Adult Pulmonary and Critical Care. NHLBI Working Group Report. Am J Respir Crit Care Med. 2020 Aug 15;202(4):511-523. doi: 10.1164/rccm.201908-1595WS.
Related Links
Access external resources that provide additional context or updates about the study.
Notice of Funding Opportunity (NOFO) for APS Consortium
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
240088
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.